Broader Scientific and Societal Considerations
| Attribute | Current Landscape | RCTD‑031’s Edge | |-----------|-------------------|-----------------| | | Anti‑fibrotic agents (e.g., nintedanib, pirfenidone) act on tyrosine kinases or TGF‑β signaling | First‑in‑class RCT‑kinase modulation | | Disease‑modifying potential | Most approved drugs slow progression but rarely reverse fibrosis | Early biomarker reversal suggests true disease modification | | Dosing convenience | Oral agents already exist, but many require multiple daily doses | Once‑daily oral formulation | | Safety window | Existing agents carry hepatic or GI toxicity | Favorable safety signal in early trials | | Market opportunity | IPF prevalence ≈ 5 / 100,000 (≈ 150k US pts); hATTR ≈ 10 k US pts | Combined addressable market > $5 bn annually | rctd-031
The ~70 % increase in net cooling power relative to RCTD‑020 stems mainly from the metasurface’s enhanced emissivity and reduced solar absorption. The high‑ZT TE legs (average ZT≈1.2 at 300 K) mitigate the typical efficiency loss at low ΔT, allowing a respectable conversion efficiency despite modest temperature differentials. Broader Scientific and Societal Considerations | Attribute |
A controller (TI TPS63070) dynamically matches the load to the TE internal resistance, ensuring optimal extraction under varying sky conditions. 000 (≈ 150k US pts)